AstraZeneca Pharma India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 14, 2024
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India held its 46th Annual General Meeting on August 14, 2025 via video conferencing, which concluded in about 51 minutes. Shareholders adopted the financial statements for the financial year ended March 31, 2025 along with the Board and Auditor reports. A dividend of Rs. 32 per equity share was declared. Ms. Hooi Bien Chuah was re-appointed as a Director (retiring by rotation), and Mr. Praveen Rao Akkinepally was appointed as Director and Managing Director for three years effective July 1, 2025. M/s. Makarand M. Joshi & Co. was appointed as secretarial auditors for a five-year term covering FY 2025-26 to FY 2029-30, and the Cost Auditor's remuneration was ratified. Voting results are awaited and will be submitted separately once the Scrutinizer's Report is received.
The Rs. 32 per share dividend is a direct return to shareholders, while the new Managing Director appointment signals a change in leadership at the Indian subsidiary. Investors should wait for the formal voting results to confirm shareholder approval of these resolutions.